GlassScriptPhysician profile
Joseph Park
NPI 1306231600
$35,502.61
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,739 · 2020: $1,519 · 2021: $496 · 2022: $1,304 · 2023: $4,771 · 2024: $7,865 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $7,508 · Consulting Fee: $6,563 · Long Term Medical Supply Or Device Loan: $616 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,618.13 |
| Travel and Lodging | $7,507.77 |
| Consulting Fee | $6,562.50 |
| Long Term Medical Supply Or Device Loan | $615.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $15,773.63 | 2019-2025 | Prostep, Inbone, Citrefix |
| Treace Medical Concepts, INC. | $6,562.50 | 2025 | |
| Arthrex, INC. | $5,155.84 | 2019-2024 | |
| Integra Lifesciences Corporation | $2,252.20 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Prodigy Surgical Distribution, INC. | $2,240.08 | 2019-2020 | |
| Orthofix Medical, INC. | $985.25 | 2019-2023 | Physio-Stim |
| Wright Medical Technology, INC. | $717.85 | 2019 | |
| Horizon Therapeutics Plc | $378.86 | 2019-2020 | |
| Osteomed LLC | $323.21 | 2019-2020 | |
| Empire Medical, INC | $184.53 | 2023 | |
| Inari Medical, INC. | $125.39 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Advanced Oxygen Therapy INC. | $114.36 | 2023 | Topical Oxygen Chamber For Extremities |
| Paragon 28, INC. | $103.75 | 2019 | |
| Angiodynamics, INC. | $75.41 | 2021 | |
| United Orthopedics LLC | $66.99 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saxum Surgical, INC. | $65.58 | 2022 | |
| Paratek Pharmaceuticals, INC. | $64.85 | 2020 | |
| Bone Support INC. | $51.12 | 2025 | Ceramentbone Void Filler, Cerament G |
| Smith+Nephew, INC. | $46.55 | 2021-2024 | |
| Solventum Corporation | $45.54 | 2024 | Activ.A.C., Promogran Prisma, Prevena |
| Misonix INC | $32.13 | 2019 | |
| Acell, INC. | $24.09 | 2020 | |
| Kerecis Limited | $23.18 | 2019 | |
| Organogenesis INC. | $19.99 | 2019 | |
| Fidia Pharma USA INC. | $18.73 | 2020 | |
| Abbvie INC. | $17.62 | 2022 | |
| Bioventus LLC | $16.97 | 2020 | |
| Mimedx Group, INC. | $16.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.